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BACAll herpesviruses encode a homolog of the herpes simplex virus type-1 UL11 tegument protein. Deletion of
UL11 disrupts virus envelopment, causes capsid accumulation within the cytoplasm, and reduces virus
release. UL11 requires acylation with myristate and palmitate for membrane binding, lipid raft trafﬁcking,
and accumulation at the site of virus envelopment. Thus, it was predicted that acylation of UL11 would be
necessary for efﬁcient virion production, similar to HIV-1 Gag which requires myristylation for virus
production. Accordingly, recombinant viruses were created to express UL11 derivatives that are not acylated,
are partially acylated, or contain foreign acylation signals. Unexpectedly, the non-acylated UL11 rescued
some growth defects of a UL11-null mutant, even though the unmodiﬁed protein was unstable. Furthermore,
a myristylated and palmitylated chimera did not fully rescue the null virus. These results suggest that UL11
maintains some function(s) when not membrane-bound, and the sequence context of the acylations is
important for UL11 function.
© 2009 Elsevier Inc. All rights reserved.Introduction
The UL11 tegument protein of herpes simplex virus type-1 (HSV-
1) is conserved among all herpesviruses, and each homolog contains
amino acid motifs that allow covalent modiﬁcations with two fatty
acids, myristate and palmitate. Without these modiﬁcations, HSV-1
UL11 lacks all membrane-binding activity and is free in the cytoplasm
(Baird et al., 2008; Loomis et al., 2001). Myristylation occurs co-
translationally on an N-terminal glycine, which is exposed following
removal of the initiator methionine (MacLean et al., 1989; Resh,
1999). Palmitylation occurs on at least one of three cysteines only
after the myristylated protein binds to the cytoplasmic face of cellular
membranes (Loomis et al., 2001). Thus, a mutant of UL11 that lacks
the glycine residue is also defective for palmitylation, even though the
cysteine residues are present (Loomis et al., 2001). Dual acylation is
necessary for the trafﬁcking of the protein through lipid rafts (or
detergent resistant membranes, DRMs) (Baird et al., 2008); however,
it remains unknown why UL11 travels this pathway. In any case, at
steady-state conditions, UL11 accumulates on membranes of the
trans-Golgi network (TGN), the site where virion envelopment occurs
to create the infectious particle (Mettenleiter, 2004; Mettenleiter
et al., 2006).
At the TGN, the envelopment process may be promoted by
bridging interactions between the membrane-bound UL11 and the
capsid-bound tegument protein UL16 (Loomis et al., 2003). This
hypothesis is supported by two lines of evidence. First, UL16 can
directly interact with UL11 in vitro (Yeh et al., 2008). Second, all UL11-ll rights reserved.null herpesviruses have defects during virion envelopment (Baines
and Roizman, 1992; Britt et al., 2004; Fulmer et al., 2007; Kopp et al.,
2003, 2004; MacLean et al., 1992; Schimmer and Neubauer, 2003;
Silva et al., 2003, 2005). As a result of the envelopment defects,
capsids accumulate within the cytoplasm of the infected cells and
fewer virions are released into the extracellular space.
In retrovirology, it is well known that fatty acids are required to
anchor the budding machinery to membranes during virion forma-
tion. In the case of HIV-1, for example, myristate-minus Gag
polyproteins fail to interact with membranes and consequently are
severely defective for virus production (Gottlinger et al., 1989).
Similarly, when HSV-1 UL11 acylation mutants have to compete with
the wild-type UL11 for incorporation into virus particles in a
transfection–infection assay, only the fully acylated form is efﬁciently
packaged (Loomis et al., 2006). Given these observations, it was
predicted that the ability of UL11 to function properly and promote
virion envelopment would require the acyl modiﬁcations. Unexpect-
edly, this was not the case, and the expression of a non-acylated UL11
rescued some growth defects of a UL11-null virus. Furthermore, a
UL11-chimera that contains foreign myristylation and palmitylation
signals at the N-terminus failed to fully rescue a UL11-null virus,
suggesting acylations alone are not sufﬁcient for protein function and
the sequence context of the modiﬁcations is also critical.
Results
Relocation of the UL11-coding sequence
The acylated residues of UL11 reside within its ﬁrst few amino
acids, but the coding sequence for these residues overlaps the reading
Table 1
Names, loci of interest, and acylations of recombinant viruses.
Virus name Parent virus UL11 locus UL35 locus Myristate Palmitate
KOS – UL11 UL35 X X
KOSBAC KOS UL11 UL35 X X
Δ30–96 KOSBAC Δ30–96 UL35
U1 Δ30–96 Δ30–96 UL11 X X
M15 Δ30–96 Δ30–96 Myr(−)
C8 Δ30–96 Δ30–96 CCC(−) X
sC6 Δ30–96 Δ30–96 sCCC(−) X
f9 Δ30–96 Δ30–96 fUL11 X X
stopM15 M15 stopΔ30–96 Myr(−)
MG16 Δ30–96 Δ30–96 Myr(−)GFP
The name of each recombinant virus, the parent virus from which it was constructed,
and the ORF present at each locus (UL11 or UL35) are indicated. The acylation state of
the UL11 variant is also indicated. “KOS” and “KOSBAC” are genetically identical, except
for the absence or presence of the bacterial artiﬁcial chromosome, respectively.
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possible to delete the 5′-coding region of UL11, or to make
substitutions of the N-terminal acylation signals of UL11, without
disrupting the function of UL12. Indeed, removal of the entire UL11-
coding sequence, including the UL12 overlap, resulted in a non-viable
virus (data not shown). The lethality of this deletion can be attributed
to the truncation of UL12 since a mutation of the UL11 start codon
(with a silent alteration in UL12) produces a virus that retains viability
(Leege et al., 2009).
To circumvent the overlap problem, the UL11-coding sequence
was relocated within a copy of the HSV-1 KOS strain genome carried
on a bacterial artiﬁcial chromosome (“BAC”; Fig. 1A). The position of
the BAC sequence within the genome does not alter the growth
properties HSV-1 (Fig. 3B) (Gierasch et al., 2006). The ﬁrst step in the
gene rearrangement was to delete the portion of UL11 that does not
overlap with UL12, creating the UL11-null mutantΔ30–96. Deletion of
the non-overlapping sequence was chosen over a substitution of the
UL11 start codon for two reasons. One, previous UL11-null viruses
have been constructed in this manner, allowing a direct comparison of
these results to published results (Baines and Roizman, 1992; Fulmer
et al., 2007; MacLean et al., 1992). And two, a spontaneous (and
undesired) reversion is less likely to occur with the deletion. Next, the
open reading frame of UL35 was replaced with the entire UL11-coding
sequence to create a recombinant named U1 (Fig. 1A). The UL35 gene,
which encodes the VP26 capsid protein, was chosen because it (1) is
not needed for growth in cell culture (the VP26-null mutant isFig. 1. Relocalization of the UL11-coding sequence. (A) Stepwise strategy used to move
the UL11-coding sequence into the UL35 locus. A recombinant of the KOS strain of HSV-1
that contains a bacterial artiﬁcial chromosome (“BAC,” 11.5 kbp) inserted between UL37
andUL38was used (“KOSBAC”). InmutantΔ30-96, all the nucleotides that do not overlap
with the essential UL12 gene were deleted, leaving the codons for the N-terminal 29
amino acids of UL11. Next, the codons at the UL35 locus were replaced with the entire
UL11-coding sequence, creating mutant U1. (B) Vero cells were infected with the
indicated viruses and harvested 24 h later. Equal numbers of infected cells were lysed in
sample buffer, separated by SDS–PAGE, and proteins were transferred to nitrocellulose.
The indicated proteins were detected by immunoblotting with the corresponding
antibodies.reduced only 50% for virus production) (Desai et al., 1998), (2) does
not overlap any other reading frames, (3) is approximately the same
size as UL11 (∼100 amino acids), and (4) is expressed late during an
infection, like UL11 (McNabb and Courtney, 1992). Both Δ30–96 and
U1 retain the ﬁrst 29 codons of the native UL11 locus (Fig. 1A and
Table 1); however, no peptide was detectable from either the cell
lysates or puriﬁed virions when examined by either immunoblotting
or radiolabeling and immunoprecipitation (data not shown). The lack
of a detectable peptide was consistent with previous UL11-null
viruses, which also left a short piece of the reading frame intact
(Baines and Roizman, 1992; Fulmer et al., 2007; MacLean et al., 1992).
The mutant genomes were transfected into Vero cells to produce
viruses for further study. As expected,Δ30–96 expressed VP26 but not
UL11, whereas U1 expressed UL11 but not VP26 (Fig. 1B). Also, the
UL11 produced from U1 was incorporated into virus particles at levels
comparable to wild-type KOSBAC (Fig. 2), although UL11 was
expressed at much higher levels in the U1-infected cells (Figs. 1B
and 2). Similar to KOS (the wild-type strain without any “BAC”
sequence), extracellular virions of KOSBAC contained UL16 (Fig. 2 and
data not shown), a tegument protein which is both soluble and
capsid-bound within the cytoplasm of infected cells (Meckes and
Wills, 2007). However, UL16 was greatly reduced for packaging intoFig. 2. UL11 expression and virion incorporation. Vero cells were infected with the
indicated viruses, and 24 h later, extracellular virions were collected from the media by
centrifugation through a 30% (wt./vol.) sucrose cushion. The virions and infected cell
lysates were separated by SDS–PAGE and transferred to nitrocellulose. The indicated
proteins were detected using corresponding antibodies. Equal numbers of infected cells
were loaded with VP5, the major capsid protein, serving as the loading control. To
achieve approximately equal VP5 levels for the “Media” samples, additional cells
(indicated as “2×” or “4×”) were infected, and the collected media were combined.
Fig. 3. Growth properties of the recombinant viruses. (A) Plaque sizes of UL11mutants. Conﬂuent monolayers of Vero cells were infected with the indicated viruses, and 4 days later,
the cells were stained with crystal violet and imaged. Plaque size was determined by measuring 10 randomly selected plaques and represented as a percent relative to U1. (B–E)
Single-step growth curve analyses of the mutants. Vero cells were infected with indicated virus and then acid-washed to inactivate any input virus that had not fused with the
cellular membrane. At the indicated times, samples were collected, and virus titers were determined by plaque assay. The results of at least two independent experiments are shown
for each mutant. (B) Comparison of the wild-type KOS strain and the recombinant carrying the bacterial artiﬁcial chromosome (“KOSBAC”). (C) Comparison of mutants that lack full-
length UL11 expression (“Δ30–96”) or express UL11 from the UL35 locus (“U1”). (D and E) Analysis of recombinant viruses that encode UL11 derivatives with altered acylation
signals. Solid lines denote PFU associated with the cells, whereas dashed lines represent PFU released into the medium.
82 N.L. Baird et al. / Virology 397 (2010) 80–88Δ30–96 virions but incorporated at wild-type levels into U1 particles
(Fig. 2), indicating that UL11, but not VP26, is needed for efﬁcient
incorporation of UL16.
To examine the replication properties of the mutants, single-step
growth curves and plaque sizes were examined. Previously described
UL11-null viruses have noticeable growth defects 24 h after infection
(Baines and Roizman, 1992; Fulmer et al., 2007; MacLean et al., 1992),
andΔ30–96 behaved identically to such clones (Fig. 3C). However, the
growth defects were far less noticeable when the infection was given
more time. This can be seen by carefully comparing the growth curves,which show that Δ30–96 was delayed many hours for the initial
production of cell-associated virus, and consequently, a delayed
release of virus into the medium was seen (Fig. 3C). Moreover, Δ30–
96 had a slower rate of release compared to KOSBAC (Fig. 3C, compare
slopes of the “Medium” lines), despite a rate of virus production in the
cell that was similar to KOSBAC once it began (Fig. 3C, compare slopes
of the “Cell” lines). After 24 h of infection, these defects resulted in
nearly a 4-log reduction in virus titer in themedium, a result similar to
what has been seen previously (Baines and Roizman, 1992). However,
after 48 h, the titer of Δ30–96 in the medium was only down about
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associated with Δ30–96 was that the plaques it produced were much
smaller than those of KOSBAC (Fig. 3A).
The effects of expressing UL11 from the UL35 locus were examined
next (virus U1), and as expected, nearly all of the growth defects of
Δ30–96 were eliminated. Only minor growth differences between
KOSBAC and U1 were evident in both its growth curve (Fig. 3C, Cell and
Medium) and plaque size (Fig. 3A). These small defects were expected
based on studies of a VP26-null virus, which was reduced only 2-fold
in its ability to produce infectious virions compared to the wild type
(Desai et al., 1998).
UL11 acylation mutants
Themain goal of these experimentswas to examine the importance
of fatty acid modiﬁcations for the functions of UL11 during virus
replication. It was predicted that acylation would be required for virus
production, as is the case for retroviruses such as HIV-1. Thus, only the
expression of a fully acylated UL11 was expected to rescue mutant
virus Δ30–96, whereas expression of partially or non-acylated UL11
derivatives would not. To test this hypothesis, recombinant viruses
were constructed to express UL11-acylation mutants from the UL35
locus. Using Δ30–96 as the parent, the UL35-coding sequence was
replaced with the previously described UL11 alleles that encode either
a myristylation mutant [Myr(−), glycine deletion] or a palmitylation
mutant [CCC(−), alanine substitution] (Fig. 4A) (Baird et al., 2008;
Loomis et al., 2001, 2006), creating the recombinant viruses M15 and
C8, respectively (Table 1). Previous studies of these UL11 alleles in
transfected cells showed that myristylation is a prerequisite forFig. 4. UL11 mutants. (A) Diagram of the wild-type and mutant forms of UL11 as
expressed from the UL35 locus. The sites of myristylation (G) and palmitylation (CCC)
are indicated with jagged lines denoting the fatty acid modiﬁcations. N-terminal
extensions corresponding to the ﬁrst 10 amino acids of v-Src [sCCC(−)] or Fyn (fUL11)
are indicated with gray lines. Fatty acid modiﬁcations are indicated and “+” indicates
basic residues. “stop” marks the location of a 2-nucleotide change that created a stop
codon in mutant Δ30–96 without altering the UL12 protein, and the dotted line
represents the remaining UL11-coding sequence downstream from the introduced stop
codon. The solid circle represents the GFP tag on the C-terminus of Myr(−)GFP. (B)
Alignment of the UL11-and UL12-coding sequences. The two-nucleotide substitution
that introduces a stop codon in the UL11 sequence without altering UL12 is indicated.palmitylation, and thus the Myr(−) derivative is not acylated at all
and fails to bind membranes; the CCC(−) mutant, on the other hand,
encodes a protein that ismyristylated but not palmitylated and retains
some membrane-binding activity (Baird et al., 2008; Loomis et al.,
2001, 2006). These properties of the two UL11 mutants were also
found when they were expressed in the context of the recombinant
viruses, M15 and C8 (Fig. 5).
Examination of the mutant proteins expressed by M15 and C8
revealed that the stability of UL11 in the infected cell was inﬂuenced
by its acylation. That is, cells infected with either virus produced UL11
variants that were efﬁciently radiolabeled and immunoprecipitated
(Fig. 5A, 35S bands); however, examination of steady-state levels by
immunoblotting revealed that the non-acylated protein from M15
was not detectable and the partially acylated protein from C8 was
barely detectable (Fig. 2, Cells). Similarly, extracellular virions from
theM15 infection contained no UL11while those produced bymutant
C8 contained only a little in immunoblot assays (Fig. 2, Media).
Furthermore, incorporation of UL16 into virions varied with the
expression of the different UL11 variants. Compared to the parental
U1 virus, M15 virions had virtually no UL16, whereas those of C8 had
reduced levels of this protein (Fig. 2, Media), again suggesting that
UL11 somehow inﬂuences the packaging of its binding partner.
The growth curves of M15 and C8 showed that expression of Myr
(−) and CCC(−) resulted in different amounts of infectious virus
released into the medium at 48 h after infection, a difference
that varied with the acylations of UL11 (Fig. 3D). As such, a
growth hierarchy was evident for the recombinants as follows:
U1NC8NM15≈Δ30–96. However, earlier time points of the same
growth curves clearly show that M15 did not behave like Δ30–96, but
actually grew better. M15 did not have the large lag period of virus
production that Δ30–96 did (compared to U1) in either the cell-
associated or the medium samples (Figs. 3C and D). In addition, the
plaques produced by M15 were ∼50% larger than those of Δ30–96
(Fig. 3A). The ability of Myr(−) to relieve some of the growth defects
of Δ30–96 was surprising because Myr(−) is not acylated and had
severely reduced protein stability, virion incorporation, and mem-
brane binding.
Why did non-myristylated UL11 enhance the growth of Δ30–96?
At least three possibilities existed for the enhanced growth
properties of M15: (1) the 29-amino acid, N-terminal peptide is
produced from the UL11 locus, interacts with full-length Myr(−)
expressed from the UL35 locus, and enables the non-myristylated
protein to bind membranes; (2) M15 has a greater speciﬁc infectivity
than Δ30–96; and (3) the Myr(−) protein can provide its function
even at very low steady-state levels by binding to some other protein
in a manner that is not dependent on its ability to bind membranes.
The ﬁrst two possibilities were readily testable. To test the trans-
complementation hypothesis, a stop codon was introduced into the
UL11 locus to eliminate expression of the peptide, creatingmutant virus
stopM15 (to create an allele named stopΔ30–96; Fig. 4A and Table 1).
Importantly, this change is silent in the essential UL12 gene (Fig. 4B).
M15 and stopM15 grewwith similar properties, which indicates that an
acylated-UL11 peptide was not acting in trans to complement Myr(−)
expressed from the UL35 locus (Fig. 6A). To test the speciﬁc infectivity
hypothesis, quantitative PCR (qPCR) was used, and this revealed that
the ratio of genome-containing particles to PFU for M15 was not
signiﬁcantly different from Δ30–96 or the parental virus (Fig. 6B).
The third possibility for the enhanced growth of M15 over Δ30–96
was that the Myr(−) protein retained some ability to interact with
other proteins, viral or cellular. This is difﬁcult to examine directly
because the protein is highly unstable. However, previous studies
using transfections showed that fusion of GFP to the C-terminus of
Myr(−) [Myr(−)GFP] stabilizes the protein so that it can be readily
detected at steady-state levels (Loomis et al., 2006). Therefore, it was
Fig. 5. Myristylation and membrane-binding properties of UL11 derivatives. (A) Vero cells were infected with the indicated viruses and radiolabeled with either [35S]methionine/
cysteine for 2.5 h or [3H]myristic acid for 30 min. All labeling periods were concluded at 9 hpi, at which time cell lysates were prepared. The UL11 derivatives were
immunoprecipitated, resolved by SDS–PAGE, and visualized by autoradiography. (B) In parallel experiments, cells were labeled for 2.5 h with [35S]methionine/cysteine, scraped
from the plates, and osmotically disrupted. The ability of the UL11 mutants to ﬂoat to the upper regions of sucrose step gradients during centrifugation was monitored.
Representative autoradiographs are shown with the tops and bottoms of the gradients indicated. (C) Phosphorimager analysis was used to quantitate the amount of membrane-
bound UL11 (top three fractions) relative to the total. The results from at least two independent experiments are shown.
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enhance the growth of Δ30–96 compared to the untagged protein. To
create such a virus, the full-length Myr(−)GFP-coding sequence was
used to replace the UL35-coding sequence of Δ30–96, making the
virus MG16 (Fig. 4 and Table 1). Critically, this new virus was created
independently from M15 in a separate recombineering reaction. And,
as expected, when Myr(−)GFP was expressed by MG16, the tagged
protein was detectable at steady-state levels, unlike its untagged
counterpart produced by M15 (Fig. 7A, “Cells”); however, the
increased stability of Myr(−)GFP did not increase the amount of
UL11-protein packaged into virions (Fig. 7A, “Media”). To compare the
abilities of the untagged and tagged proteins to rescue growth ofΔ30–
96, single-step growth curves of M15 and MG16 were performed
(Fig. 7B). As seen by the “Medium” lines (dashed), MG16 did not
release infectious virus into the medium any better than M15.
However, the “Cell” lines (solid) suggest that MG16 may have
produced more cell-associated virus than M15.
Fusion of foreign acylation signals to UL11
The fatty acids on UL11 appear to be required for efﬁcient virion
biogenesis; however, it is quite clear that they are also critical for
membrane binding (Baird et al., 2008; Loomis et al., 2001). Therefore,
it is possible that UL11 simply requiresmembrane binding, but not the
speciﬁc combination of myristylation and palmitylation, for its
function. To test this hypothesis, the coding sequence for a previously
described chimera of UL11 that binds membranes efﬁciently and
independently of palmitylation, sCCC(−) (Baird et al., 2008), wasinserted into the UL35 locus to create virus sC6 (Fig. 4A and Table 1).
This mutant has the 10-amino acid membrane-binding domain of the
Rous sarcoma virus oncoprotein (v-Src) fused to the N-terminus of
CCC(−). For sCCC(−), membrane binding is mediated only by the
myristate and basic residues of the v-Src peptide. In another construct,
fUL11, the 10-amino acid membrane-binding domain of the cellular
Fyn protein was added to the N-terminus of UL11 (Fig. 4A). This
chimera contains sites for myristylation and palmitylation within the
Fyn peptide but also retains the UL11 palmitylation site (Baird et al.,
2008; Loomis et al., 2001). Insertion of the fUL11-coding sequence
into UL35 created virus f9 (Table 1).
Following infection of cells with either sC6 or f9, the chimeric UL11
proteins were found to be expressed at high steady-state levels
(Fig. 2) and myristylated (Fig. 5A). Both chimeras appeared to bind
membranes better than the wild type (Figs. 5B and C), but only the
myristylated and palmitylated fUL11 construct was incorporated into
virions as efﬁciently as the wild-type protein produced by virus U1
(Fig. 2). Thus, it seems that the dual acylation of UL11may be required
for packaging, with other mechanisms of membrane binding being
inferior; however, sC6 and f9 mutants have N-terminal sequence
differences that could also account for the differences in their ability
to be incorporated and support viral growth. Moreover, the amount of
UL16 incorporated into sC6 and f9 particles was again dependent on
the packaging levels of the UL11 variants (Fig. 2).
To measure the ability of the chimeric proteins to rescue the Δ30–
96 mutant, the plaque sizes and growth curves of sC6 and f9 were
examined. Expression of either sCCC(−) or fUL11 increased the
plaque size of Δ30–96, but only fUL11 restored the plaques to the size
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revealed that expression of the dually acylated fUL11 was not
functionally equivalent to wild-type UL11 (Fig. 3E). That is, virus f9
did not produce cell-associated virus or release virus into the medium
as efﬁciently as U1; but, expression of fUL11 did rescue growth of
Δ30–96 better than (16–24 h) or equal to (48 h ) sCCC(−), implying
dual acylation is better than mono acylation.
The most distinct and unexpected result obtained with the
chimeras was a delay in the production of infectious sC6 within the
cell without a delay of virus release into the medium (Fig. 3E). That is,
this mutant has the unusual property of producing infectious virus
within the cell at the same time virus is released into the medium.
Discussion
The experiments in this study were designed to examine the
importance of UL11 acylation for protein function during envelop-
ment and release of HSV-1 particles. It was predicted that the
modiﬁcations would be required and that expression of a non-
acylated UL11 variant would not rescue the growth of the UL11-null
virus, Δ30–96. However, the data presented here show thatFig. 6. Further characterization of mutant M15. (A) The growth properties of M15 and
stopM15were compared, revealing that the 29-amino acid N-terminal peptide does not
trans-compliment. The results from two independent experiments are shown. (B) To
compare the speciﬁc infectivities of the indicated mutant virus stocks, samples were
treated with DNase to eliminate any DNA that was not contained in virions, and viral
DNA was subsequently puriﬁed. The numbers of genomes present in each sample were
measured by quantitative PCR and normalized for PFUs. The limit of detection was 100
copies per PCR. The results from at least two independent experiments are shown. (C)
To ensure that the DNase treatments were effective, random PCR products were
incubated with (+) or without (−) the enzyme. “Input” is the initial amount of PCR
product in each sample. A representative agarose gel stained with ethidium bromide is
shown.
Fig. 7. Addition of GFP stabilizes Myr(−)UL11 but does not enhance growth of the
recombinant virus. Vero cells were infected with the indicated viruses. Cell and virus
samples were harvested, and proteins were separated by SDS–PAGE. The indicated
proteins were detected using the corresponding antibodies. (B) Single-step growth
curves were performed as described in the legend to Fig. 3.expression of the non-acylated protein (virus M15) partially rescued
the growth defects seen with Δ30–96, despite being highly unstable,
implying that some function was maintained. Furthermore, not all
combinations of myristylation and palmitylation are sufﬁcient for
UL11 function because expression of the dually acylated fUL11
chimera (virus f9) did not completely rescue Δ30–96. This suggests
the context of the acylations is also critical for UL11 function.
Why did the non-acylated Myr(−) protein enhance the growth of
Δ30–96 although it does not bindmembranes, does not accumulate at
the TGN or in DRMs, and is not stable? One possible explanation is that
Myr(−) may interact with an unknown protein, either cellular or
viral, to promote the enhanced growth properties of M15. Bacterially
produced UL11, which is not acylated, interacts with UL16 (Loomis
et al., 2003; Yeh et al., 2008); hence, Myr(−) may interact with either
soluble or capsid-bound UL16 to inﬂuence interactions between the
capsid and the TGN membrane that eventually lead to the formation
of the viral membrane during ﬁnal envelopment. Alternatively, UL11
also interacts in some manner with the tails of the glycoproteins gD
and gE (Farnsworth et al., 2007) and perhaps the unmyristylated
protein can promote virus growth through those interactions. If so,
then only small amounts must be needed because only 5% of Myr(−)
ﬂoats with membranes, versus N60% of dually acylated UL11.
To stabilize, and therefore increase the chances of interactions
between Myr(−) and other proteins, a GFP tag was fused to the
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readily detectable at steady-state levels. Though the increase in
protein concentration had no affect on incorporation of the UL11-var-
iant into virus particles and release of virus into the medium, an
increase of cell-associated virus was observed. These results suggest
that expression of Myr(−)GFP promotes the formation of infectious
virionswithin the cell better than the untaggedMyr(−). However, the
MG16 virions are not efﬁciently released into the medium, supporting
the hypothesis that UL11 has a post-envelopment function, such as
transport of virus-containing vesicles to the cell periphery.
Comparing the growth data of viruses MG16 and M15 also
demonstrates that no secondary mutations are present within either
viral genome. Since viruses M15 and MG16 were created totally
independent of each other, yet behave quite similarly (despite the
great differences in protein stability), it is unlikely that a secondary
mutation is present in M15 that promoted the unexpected growth.
Furthermore, because Δ30–96 (the parent virus to both M15 and
MG16; Table 1) behaves like previously constructed UL11-null viruses
(Baines and Roizman, 1992; Fulmer et al., 2007; MacLean et al., 1992),
it is unlikely that a mutation in the viral genome was present in this
clone that could ultimately have caused the unexpected growth of
M15.
In addition to requiring fatty acids for full function, the data
presented here show that the sequence context of the fatty acids is
important. Recombinant f9 encodes a UL11 derivative with an
acylation pattern similar to wild-type UL11 and behaves similarly to
UL11 with respect to membrane binding, DRM association, and virion
incorporation. However, despite these similarities, virus f9 did not
grow as efﬁciently as the U1 parent, although expression of fUL11 did
rescue growth of Δ30–96 better than all the other UL11 mutants. The
growth defects seen with virus f9 may have occurred because the
addition of the peptide altered the structure of UL11, thereby
inhibiting proper interactions with other proteins. However, the
interaction with UL16 seems to be normal based on the high levels of
packaging of this binding partner observed for the f9 virus. Also, it is
possible that the basic residues within the Fyn peptide altered the
ability of fUL11 to be released from membranes. That is, wild-type
UL11 relies on myristate and palmitate for membrane binding, and
the latter modiﬁcation is reversible, leaving only a myristyl group.
Since the membrane-binding strength of myristate alone is low, non-
palmitylated UL11 would “slip” on and off membranes readily. In
contrast, the Fyn peptide contains basic residues, which bind acidic
phospholipids (Sigal et al., 1994), and these could enable fUL11 to
irreversibly bind to membranes. While it remains to be seen whether
UL11 exhibits dynamic interactions with membranes, the enhanced
growth properties of viruses M15 (unmodiﬁed UL11) and C8 (only
myristylated) relative to the parental Δ30–96 (null) virus are
intriguing.
The growth properties of the virus sC6 were unique and
unexpected. Unlike all the other recombinants, the lag period
between production of this virus within the cell and its release into
the medium was eliminated (or reduced to less than 8 h). If UL11 is
involved with transport of virus-containing vesicles to the plasma
membrane, then it is possible that the sCCC(−) chimera somehow
accelerates the rate of egress. For example, because this highly
expressed chimera does not trafﬁc to DRMs (Baird et al., 2008) and is
poorly packaged into virions (Fig. 2), it may trafﬁc to a subcellular
location where it is better able to provide an egress function, as
opposed to an envelopment function. Alternatively, the Src peptide is
well known to be an efﬁcient plasma membrane-targeting signal, and
it is conceivable that the modiﬁed UL11 protein promotes ﬁnal
envelopment at the cell surface. This model seems less likely since no
evidence was found for it when sC6-infected cells were examined by
electron microscopy (data not shown).
Another striking observation from these studies was the clear
correlation between packaging of UL11 and UL16. A similarobservation has been seen for a UL11-null mutant of pseudorabies
virus (Klupp et al., 2005). This might be explained by either of two
models. First, there is a population of UL16 that is capsid-bound
(Meckes and Wills, 2007), and it is possible that an interaction with
UL11 is needed for this population to stay on capsids and to be
packaged. Second, the population of capsid-bound UL16 may only
represent a small fraction of the UL16 that is foundwithin virions, and
the bulk of UL16 might be recruited by UL11 during envelopment.
Further studies are needed to better understand the interplay
between UL11 and UL16 during virion assembly.
Materials and methods
Cells and viruses
Vero cells were grown in Dulbecco's modiﬁed Eagle's medium
(DMEM, Invitrogen) supplemented with 5% fetal bovine serum (FBS)
and penicillin/streptomycin (Gibco, 15140-148). All infections were
performed in DMEM supplementedwith 2% FBS, 25mMHEPES buffer,
glutamine (0.3 μg/ml), penicillin, and streptomycin. All viruses were
derived from the KOS strain of HSV-1 (Smith, 1964).
Recombinant viruses
“KOSBAC” is a bacterial artiﬁcial chromosome that contains the
HSV-1 KOS strain genome (Gierasch et al., 2006). Recombinant HSV-1
clones were made via “recombineering” methods with a galK-based
positive/negative selection system (Warming et al., 2005). All UL11-
coding sequences inserted into the UL35 locus were PCR ampliﬁed
from plasmids that have been described previously (Baird et al., 2008;
Loomis et al., 2001, 2003, 2006).
All viral clones were analyzed for DNA integrity by two methods.
First, the locus of interest was PCR ampliﬁed and sequenced. Second,
total DNA was isolated for each virus and monitored for large
deletions and rearrangements (data not shown). The bacterial
sequence (“BAC”) was left in the HSV-1 genome for all recombinants.
Following recombineering, high-quality viral DNA was obtained
from the bacteria using the Qiagen Large Construct kit (cat. no.
12462). Puriﬁed DNA was transfected into Vero cells (35-mm dishes,
∼50% conﬂuent) using Lipofectamine 2000 (Invitrogen, cat. no.
11668-019). Five days after transfection, the cells were scraped off
the plates, frozen/thawed 3 times, and cell debris was removed by
centrifugation. New monolayers of Vero cells were infected with the
cleared lysate to produce a viral stock. DNA was puriﬁed from the
resulting virus stocks using the Qiagen DNeasy Blood and Tissue Kit
(cat. no. 69504) and the locus of interest was sequenced to verify the
mutations. Virus stock preparations were also titered, as follows. Vero
cells were infected in duplicate wells for 1 h at 37°C. After incubation,
the cells were washed with either 1% FBS in PBS (“PBS titer”) or an
acid wash (135 mM NaCl, 10 mM KCl, 40 mM citric acid, pH 3.0)
followed by 1% FBS in PBS (“acid titer”). Cells were overlaid with 0.5%
(wt./vol.) methylcellulose for 4 days, stained with crystal violet, and
plaques counted.
Antibodies
UL11-speciﬁc antibodies were developed in rabbits and have been
described previously (Loomis et al., 2003). Antibodies against VP5 and
VP26 were kindly provided by Richard Courtney, The Pennsylvania
State University.
Growth curves
Vero cells (5×105/well) were infected with speciﬁed virus at a
multiplicity of infection (MOI) of 1 (based on “acid titer”) at 37°C.
After 1 h of adsorption, free virus was aspirated and cells werewashed
87N.L. Baird et al. / Virology 397 (2010) 80–88sequentially with an acid wash (135 mM NaCl, 10 mM KCl, 40 mM
citric acid, pH 3.0) and 1% FBS in PBS, then overlaidwith 1ml of DMEM
containing 2% FBS. At indicated times after infection, medium and
cells were harvested from a single well. Medium was cleared of cells,
and frozen. Cells were resuspended in PBS, washed 1× with PBS, and
freeze/thawed 3 times to release virus. Each sample (“Medium” and
“Cell”) was then titered on Vero cells as detailed above.
Membrane ﬂotation
Membranes were isolated using a previously described ﬂotation
protocol (Baird et al., 2008; Spearman et al., 1997). Brieﬂy, Vero cells
(1.2×107) were infected at an MOI of 10 (“PBS titer”). At 5.5 hpi,
cells were starved in DMEM lacking methionine and cysteine for
30 min. Post-starvation, cells were radiolabeled with an L-[35S]
methionine–cysteine mix (300 μCi/plate, N1000 Ci/mmol) for 2.5 h,
scraped off the plates, and washed in cold NTE (10 mM Tris–HCl, pH
7.4, 100 mM NaCl, 1 mM EDTA). After pelleting, cells were
resuspended and swollen in hypotonic lysis buffer (10 mM Tris–
HCl, pH 7.4, 0.2 mMMgCl2) on ice for 30 min. Cells were lysed at 4 °C
by 30 strokes with a dounce homogenizer and then centrifuged at
low speed. Post-nuclear supernatants were mixed with 65%
(wt./wt.) sucrose (58% ﬁnal, 2.0 ml total), placed in the bottom of
a Beckman SW55 Ti tube, and sequentially overlaid with 2.0 ml of
45% sucrose and 1.0 ml of 2.5% sucrose. All sucrose solutions were
made in NTE buffer. The samples were centrifuged for 18 h at
200,000×g and 4 °C in a Beckman ultracentrifuge, and six equal-
volume fractions were collected from the top. UL11 was immuno-
precipitated using rabbit anti-UL11 antibodies, separated by SDS–
PAGE, and quantitated by phosphorimager.
Incorporation assay
Virion incorporation was monitored using a published protocol
(Loomis et al., 2006), modiﬁed as described below. Vero cells were
infected at an MOI of 1 (“PBS titer”) and 24 hpi, medium was
collected and cleared of cellular debris. Virions were pelleted from
the supernatant by centrifugation through a 30% (wt./vol.) sucrose
cushion (1 ml) at 4°C using a Beckman SW41 Ti at 83,500×g for 1 h.
Infected cells were scraped into PBS, pelleted, and resuspended in
sample buffer. Samples were then sonicated at maximum power for
3 min. Cell lysates and collected virions were separated by SDS–PAGE
and analyzed by Western blot using speciﬁed antibodies. For the
“Cells” samples, lysates of equal numbers of cells were loaded on the
gel for each mutant, and this resulted in approximately equal
amounts of VP5 (the major capsid protein). To achieve approximately
equal VP5 levels for the “Media” samples, some mutants required
that additional cells be infected and the collected media were
combined.
Myristylation of UL11
Vero cells were seeded into parallel plates: 100-mm dish
(3×106) and 35-mm dish (6×105). The next day, the cells were
infected with the designated virus at an MOI of 10 (“PBS titer”). At
6 hpi, the 35-mm dishes were starved for 30 min, then radiolabeled
with an L-[35S] methionine–cysteine mix (300 μCi/ml, N1000 Ci/
mmol) for 2.5 h (3 h total, 6–9 hpi). Concurrent with the ﬁnal 0.5 h
of the 35S label (8.5–9 hpi), the 100-mm dishes were radiolabeled
with [3H]myristic acid (300 μCi/ml, 30 Ci/mmol) for 30 min in
serum-free DMEM. After labeling, cells were mixed with RIPA buffer,
and the UL11 proteins were immunoprecipitated with polyclonal
anti-UL11 antiserum. Immunoprecipitated proteins were separated
by SDS–PAGE. Gels were treated with EN3HANCE (PerkinElmer) as
per manufacturer's instructions prior to drying and exposure to
autoradiography ﬁlm.Quantitative PCR analysis
Using prepared virus stocks, DNA was extracted from 1×107 PFU
(“PBS titer”). Virus was mixed with PBS, layered onto a sucrose
cushion (30%, wt./vol.), and centrifuged at 4 °C in a Beckman
TLA100.3 at 83,500×g for 1 h. Viral pellets were resuspended in
water and treated with DNase I (0.1 U/μl; New England Biolabs,
M0303) for 30 min at 37 °C. The enzyme was inactivated by
incubation at 75 °C for 10 min. Samples were pelleted again as
above, but without a sucrose cushion. Next, virions were resuspended
in PBS, and DNA was isolated using the Qiagen DNeasy Blood and
Tissue Kit (cat. no. 69504). Quantiﬁcation of viral DNA copy number
was made using an Opticon 2 real-time PCR machine (BioRad).
Ampliﬁcation was performed using iQ SYBR Green Supermix (BioRad,
170-8880). HSV-1 speciﬁc primers (forward, 5′-CACAGGCGGGACAC-
CAGC; reverse, 5′-CCTCCGCAATCCCAAGATTC) were utilized to am-
plify a 97-bp fragment from the UL13 gene. The HSV genome copy
number was determined against a standard curve constructed by
serial dilution of DNA isolated from the WT virus, KOSBAC. Limit of
detection for viral DNA was 100 copies per PCR reaction (20 μl).Acknowledgments
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